Afficher les filtres
Type de ressources
Filtrer par Type de ressources
Pathologies
Filtrer par Pathologies
Technologies
Filtrer par Technologies
Instruments
Filtrer par Instruments
73 Résultat(s) trouvé(s)
Trié par:

Unlocking the power of anti-MCV detection for early diagnosis of Rheumatoid Arthritis

Webinaire
Jun. 07, 2024

Educational Workshop with Holger Bang, PhD & Roberto Fiorillo

May. 17, 2024 May. 20, 2024

Événement
Ljubljana, Slovenia

14th International Congress on Autoimmunity 2024

Sebia booth #15

En savoir plus

Sebia receives U.S. FDA Clearance for the CAPILLARYS 3 DBS devices

Communiqué de presse
Apr. 11, 2024

The next generation instrument for screening hemoglobin disorders in newborns.

Apr. 18, 2024 Apr. 20, 2024

Événement
Torino, Italy

European Myeloma Network Meeting – EMN 2024

Sebia booth: #9

En savoir plus

Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays

Communiqué de presse
Mar. 06, 2024

Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.

How External Quality Assessment supports quality improvement in laboratory hemoglobinopathy diagnosis

Webinaire
Feb. 19, 2024

Educational Workshop with Dr. Barbara De la Salle

HYDRASYS 2 SCAN FOCUSING: Overview

Vidéo
Feb. 13, 2024

Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.

Sebia launches M-inSight®, a test for monitoring multiple myeloma patients

Communiqué de presse
Dec. 04, 2023

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma